Effects and mechanisms of trifluridine alone or in combination with cryptotanshinone in inhibiting malignant biological behavior of gastric cancer

References

• Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–279.
   PubMed Web of Science ®Google Scholar
• Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534–542.
   PubMed Web of Science ®Google Scholar
• Sexton RE, Al Hallak MN, Diab M, et al. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39(4):1179–1203.
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167–192.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Orouei S, et al. Recent advances and future directions in anti-tumor activity of cryptotanshinone: a mechanistic review. Phytother Res. 2021;35(1):155–179.
   PubMed Web of Science ®Google Scholar
• Wu YH, Wu YR, Li B, et al. Cryptotanshinone: a review of its pharmacology activities and molecular mechanisms. Fitoterapia. 2020;145:104633.
   PubMed Web of Science ®Google Scholar
• Li H, Gao C, Liu C, et al. A review of the biological activity and pharmacology of cryptotanshinone, an important active constituent in Danshen. Biomed Pharmacother. 2021;137:111332.
   PubMed Web of Science ®Google Scholar
• Chen ZM, Huang L, Li MM, et al. Inhibitory effects of isocryptotanshinone on gastric cancer. Sci Rep. 2018;8(1):9307.
   PubMedGoogle Scholar
• Wang J, Zhang G, Dai C, et al. Cryptotanshinone potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3 activity. J Int Med Res. 2017;45(1):220–230.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lu HL, Liu YD, et al. Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma growth by inhibiting the JAK/STAT3 signaling pathway. Biomed Pharmacother. 2017;95:1388–1396.
   PubMed Web of Science ®Google Scholar
• Shen L, Zhang G, Lou Z, et al. Cryptotanshinone enhances the effect of arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo. BMC Complement Altern Med. 2017;17(1):106.
   PubMedGoogle Scholar
• Chakrabarti S, Wintheiser G, Tella SH, et al. TAS-102: a resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies. Pharmacol Ther. 2021;224:107823.
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev. 2015;41(9):777–783.
   PubMed Web of Science ®Google Scholar
• Vodenkova S, Buchler T, Cervena K, et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447.
   PubMed Web of Science ®Google Scholar
• Emura T, Suzuki N, Yamaguchi M, et al. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 2004;25(3):571–578.
   PubMed Web of Science ®Google Scholar
• Baba Y, Tamura T, Satoh Y, et al. Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine. Mol Oncol. 2017;11(8):1065–1077.
   PubMed Web of Science ®Google Scholar
• Meng L, Chen Z, Jiang Z, et al. MiR-122-5p suppresses the proliferation, migration, and invasion of gastric cancer cells by targeting LYN. Acta Biochim Biophys Sin (Shanghai). 2020;52(1):49–57.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446.
   PubMed Web of Science ®Google Scholar
• Kitao H, Morodomi Y, Niimi S, et al. The antibodies against 5-bromo-2′-deoxyuridine specifically recognize trifluridine incorporated into DNA. Sci Rep. 2016;6(1):25286.
   PubMedGoogle Scholar
• Wong MCS, Huang J, Chan PSF, et al. Global incidence and mortality of gastric cancer, 1980-2018. JAMA Netw Open. 2021;4(7):e2118457.
   PubMed Web of Science ®Google Scholar
• Mikuni H, Boku N. III. chemotherapy for gastric cancer -revised points of the 6th edition of Japanese Gastric Cancer Treatment Guidelines. Gan To Kagaku Ryoho Cancer & Chemotherapy. 2021;48(9):1121–1125.
   PubMedGoogle Scholar
• Xu W, Li B, Xu M, et al. Traditional Chinese medicine for precancerous lesions of gastric cancer: a review. Biomed Pharmacother. 2022;146:112542.
   PubMed Web of Science ®Google Scholar
• Wang FH, Zhang XT, Li YF, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021;41(8):747–795.
   PubMed Web of Science ®Google Scholar
• Kotani D, Fukuoka S, Yoshino T. Efficacy of TAS-102. Gan To Kagaku Ryoho Cancer & Chemotherapy. 2015;42(1):1–5.
   PubMedGoogle Scholar
• Shitara K, Doi T, Dvorkin M, et al. Trifluridine/Tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437–1448.
   PubMed Web of Science ®Google Scholar
• Doi T, Yoshino T, Fuse N, et al. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Invest New Drugs. 2015;33(5):1068–1077.
   PubMed Web of Science ®Google Scholar
• Cecchini M, Kortmansky JS, Cui C, et al. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer. 2021;127(9):1417–1424.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Yamada T, Kamiyama H, et al. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: tAS-CC3 study. Int J Clin Oncol. 2021;26(1):111–117.
   PubMed Web of Science ®Google Scholar
• Escargueil AE, Larsen AK. Mitosis-specific MPM-2 phosphorylation of DNA topoisomerase IIalpha is regulated directly by protein phosphatase 2A. Biochem J. 2007;403(2):235–242.
   PubMedGoogle Scholar
• Tapia C, Kutzner H, Mentzel T, et al. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30(1):83–89.
   PubMed Web of Science ®Google Scholar
• Baba T, Kokuryo T, Yamaguchi J, et al. Pre-exposure to fluorouracil increased trifluridine incorporation and enhanced its anti-tumor effect for colorectal cancer. Anticancer Res. 2018;38(3):1427–1434.
   PubMed Web of Science ®Google Scholar
• Laudisi F, Cherubini F, Monteleone G, et al. STAT3 interactors as potential therapeutic targets for cancer treatment. Int J Mol Sci. 2018;19(6):1787.
   PubMed Web of Science ®Google Scholar
• Huang Q, Zhong Y, Dong H, et al. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go? Eur J Med Chem. 2020;187:111922.
   PubMed Web of Science ®Google Scholar
• Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.
   PubMed Web of Science ®Google Scholar
• Park SY, Lee CJ, Choi JH, et al. The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance. J Exp Clin Cancer Res. 2019;38(1):399.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Song J, Tang B, et al. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway. J Exp Clin Cancer Res. 2020;39(1):259.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Miyamoto M, Aoyama T, et al. JAK2/STAT3 pathway as a therapeutic target in ovarian cancers. Oncol Lett. 2018;15(4):5772–5780.
   PubMed Web of Science ®Google Scholar
• Najafi M, Ahmadi A, Mortezaee K. Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review. Cell Biol Int. 2019;43(11):1206–1222.
   PubMed Web of Science ®Google Scholar